Education
About Us
Working with TipRanks
Follow Us
CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
RESEARCH TOOLSreports
Total Valuation
CytoMed Therapeutics Limited has a market cap or net worth of $26.77M. The enterprise value is $35.99M.
Market Cap$26.77M
Enterprise Value$35.99M
Share Statistics
CytoMed Therapeutics Limited has 11,540,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,540,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CytoMed Therapeutics Limited’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -24.91%.
Return on Equity (ROE)-0.37
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-24.91%
Return on Capital Employed (ROCE)-0.25
Revenue Per Employee10.38K
Profits Per Employee-111.85K
Employee Count28
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CytoMed Therapeutics Limited is -16.63. CytoMed Therapeutics Limited’s PEG ratio is 3.48.
PE Ratio-16.63
PS Ratio0.00
PB Ratio6.13
Price to Fair Value6.13
Price to FCF-19.76
Price to Operating Cash Flow-20.02
PEG Ratio3.48
Income Statement
In the last 12 months, CytoMed Therapeutics Limited had revenue of 290.56K and earned -3.13M in profits. Earnings per share was -0.29.
Revenue290.56K
Gross Profit213.09K
Operating Income-2.91M
Pretax Income-3.13M
Net Income-3.13M
EBITDA-2.94M
Earnings Per Share (EPS)-0.29
Cash Flow
In the last 12 months, operating cash flow was -1.91M and capital expenditures -429.92K, giving a free cash flow of -1.30M billion.
Operating Cash Flow-1.91M
Free Cash Flow-1.30M
Free Cash Flow per Share-0.11
Dividends & Yields
CytoMed Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change7.91%
50-Day Moving Average2.51
200-Day Moving Average2.28
Relative Strength Index (RSI)46.06
Average Volume (3m)26.64K
Important Dates
CytoMed Therapeutics Limited upcoming earnings date is Nov 14, 2025, TBA Not Confirmed.
Last Earnings DateApr 28, 2025
Next Earnings DateNov 14, 2025
Ex-Dividend Date―
Financial Position
CytoMed Therapeutics Limited as a current ratio of 14.08, with Debt / Equity ratio of 4.21%
Current Ratio14.08
Quick Ratio14.08
Debt to Market Cap<0.01
Net Debt to EBITDA2.91
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CytoMed Therapeutics Limited has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate>-0.01
Enterprise Valuation
CytoMed Therapeutics Limited EV to EBITDA ratio is -14.82, with an EV/FCF ratio of -16.52.
EV to Sales149.85
EV to EBITDA-14.82
EV to Free Cash Flow-16.52
EV to Operating Cash Flow-16.74
Balance Sheet
CytoMed Therapeutics Limited has $4.78M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$4.46M billion.
Cash & Marketable Securities$4.78M
Total Debt$0.00
Net Cash-$4.46M
Net Cash Per Share-$0.39
Tangible Book Value Per Share$1.06
Margins
Gross margin is 25.15%, with operating margin of -1002.20%, and net profit margin of -1077.85%.
Gross Margin25.15%
Operating Margin-1002.20%
Pretax Margin-1077.75%
Net Profit Margin-1077.85%
EBITDA Margin-1011.10%
EBIT Margin-1037.76%
Analyst Forecast
The average price target for CytoMed Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast38.80%